Enter values to see results
—
/hr
—
hours
—
mg·h/L
—
Enter values to see results
—
/hr
—
hours
—
mg·h/L
—
The Vancomycin AUC Calculator estimates the 24-hour area under the concentration-time curve (AUC₂₄) for vancomycin, which is now the recommended pharmacokinetic/pharmacodynamic target for therapeutic drug monitoring. In 2020, the ASHP, IDSA, SIDP, and PIDS released updated consensus guidelines recommending AUC-guided vancomycin monitoring (target AUC₂₄/MIC ratio of 400-600 mg·h/L, assuming MIC of 1 mg/L) over traditional trough-only monitoring for serious MRSA infections.
Vancomycin is a glycopeptide antibiotic and remains the first-line treatment for serious methicillin-resistant Staphylococcus aureus (MRSA) infections, including bacteremia, endocarditis, osteomyelitis, pneumonia, and complicated skin and soft tissue infections. Despite decades of clinical use, optimizing vancomycin dosing continues to challenge clinicians due to its narrow therapeutic index, variable pharmacokinetics, and the association between supratherapeutic exposure and nephrotoxicity.
Historically, vancomycin monitoring relied on trough concentrations, with targets of 15-20 mg/L for serious infections. However, accumulating evidence demonstrated that targeting troughs of 15-20 mg/L was associated with increased nephrotoxicity without clear efficacy benefit. The AUC₂₄/MIC ratio of 400-600 better predicts clinical outcomes and allows lower trough levels (often 10-15 mg/L), reducing nephrotoxicity risk while maintaining efficacy.
The two-level (first-order pharmacokinetic) method, implemented in this calculator, uses measured peak and trough concentrations to calculate the patient's individual elimination rate constant (ke) and half-life, then estimates AUC₂₄ using the trapezoidal rule. This approach requires drawing two levels: a trough (within 30 minutes before the next dose) and a peak (1-2 hours after the end of infusion) at steady state (typically after the 4th dose for q12h or 3rd dose for q8h dosing).
The elimination rate constant is calculated as ke = ln(Cmax/Cmin) / time between levels. The AUC for one dosing interval is estimated using trapezoidal approximation, then extrapolated to 24 hours by multiplying by the number of doses per day. Target AUC₂₄ of 400-600 mg·h/L (assuming MIC = 1 mg/L) corresponds to AUC/MIC of 400-600, the range associated with optimal clinical outcomes and minimized nephrotoxicity.
Alternative approaches include Bayesian software (more sophisticated, allows one-level estimation) and first-dose AUC estimation using population pharmacokinetic models. However, the two-level method provides a straightforward, transparent calculation suitable for clinical settings without access to Bayesian dosing software. Many health systems have successfully implemented two-level AUC monitoring as their standard approach.
Key considerations for accurate AUC estimation include proper sample timing, ensuring steady state has been achieved, accounting for changes in renal function, and recognizing that the MIC of the infecting organism significantly impacts the AUC/MIC ratio. For isolates with MIC > 1 mg/L, alternative antibiotics should be strongly considered regardless of the AUC achieved.
This calculator provides clinical pharmacokinetic parameter estimation and AUC₂₄ calculation to support AUC-guided vancomycin therapeutic drug monitoring according to current consensus guidelines.
Using measured peak (Cmax) and trough (Cmin) levels, the calculator determines: ke = ln(Cmax/Cmin) / time between levels, half-life = 0.693/ke. AUC for one dosing interval is calculated using trapezoidal method: AUC_interval = (Cmax - Cmin)/ke + (Cmin × tau). AUC₂₄ = AUC_interval × (24/tau). Target AUC₂₄/MIC = 400-600 mg·h/L (MIC assumed 1 mg/L).
AUC₂₄ < 400: Subtherapeutic — dose increase recommended for efficacy. AUC₂₄ 400-600: Therapeutic target range — optimal efficacy with acceptable safety profile. AUC₂₄ > 600: Supratherapeutic — dose reduction recommended to minimize nephrotoxicity risk. Monitor serum creatinine every 48-72 hours. Reassess if renal function changes. For organisms with MIC > 1, consider alternative agents.
Inputs
Results
AUC₂₄ of 504: within target range of 400-600; maintain current dosing.
Inputs
Results
AUC₂₄ of 732: above target; dose reduction to ~1000mg q12h recommended.
Evidence showed that the AUC₂₄/MIC ratio of 400-600 better predicts vancomycin efficacy than trough levels alone. Targeting troughs of 15-20 mg/L often resulted in AUC values exceeding 600, increasing nephrotoxicity without improving outcomes. AUC-guided dosing allows lower troughs (10-15) that still achieve therapeutic AUC targets.
For two-level AUC estimation: Trough — within 30 minutes before the next dose. Peak — 1-2 hours after the end of infusion. Both levels should be drawn at steady state: after 3-4 doses for standard dosing, or after 24-48 hours of continuous infusion. Ensure accurate documentation of draw times.
The 2020 consensus guidelines recommend an AUC₂₄/MIC target of 400-600 mg·h/L for serious MRSA infections. This assumes an MIC of 1 mg/L (the typical MRSA susceptibility breakpoint). If the actual MIC is known, divide the calculated AUC₂₄ by the MIC for the true AUC/MIC ratio.
For vancomycin MICs of 2 mg/L, achieving an AUC/MIC of 400 would require AUC₂₄ of 800, which exceeds safe levels. Guidelines recommend considering alternative agents (daptomycin, linezolid, ceftaroline, trimethoprim-sulfamethoxazole) when the vancomycin MIC is ≥2 mg/L.
Bayesian software uses population pharmacokinetic models combined with patient data (demographics, renal function, drug levels) to estimate AUC. It can work with a single level and provides more robust estimates, especially early in therapy. The two-level method requires measured peak and trough but is simpler and more transparent.
Vancomycin is primarily renally eliminated (>80%). Decreased renal function reduces clearance, prolongs half-life, and increases AUC for a given dose. Dose adjustments are essential in renal impairment. AUC monitoring should be repeated when renal function changes significantly (>0.5 mg/dL creatinine change).
Vancomycin nephrotoxicity is defined as a ≥0.5 mg/dL or ≥50% increase in serum creatinine on two consecutive measurements. Risk factors include AUC₂₄ >600, concomitant nephrotoxins (aminoglycosides, piperacillin-tazobactam), prolonged therapy, ICU status, and pre-existing renal impairment.
Single-trough AUC estimation uses population pharmacokinetic equations to estimate AUC from a trough level. While less accurate than two-level methods, certain validated equations (e.g., the Neely model) provide reasonable estimates. Bayesian methods with one level generally outperform empiric equations.
Initial AUC assessment should occur at steady state (after 3-4 doses). Repeat monitoring is recommended: every 48-72 hours in unstable patients, when renal function changes, after dose adjustments (allow new steady state), and weekly in stable patients on prolonged therapy.
AUC-guided monitoring is most important for serious MRSA infections (bacteremia, endocarditis, osteomyelitis, pneumonia). For less severe infections or empiric short courses, clinical judgment may determine whether full AUC monitoring is necessary. Trough-only monitoring remains acceptable in some clinical situations.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
Heparin Dosing Calculator
Pharmacology & Drug Dosing Calculators
Warfarin Dosing Calculator
Pharmacology & Drug Dosing Calculators
Ketamine Dosing Calculator
Pharmacology & Drug Dosing Calculators
Lidocaine Dosing Calculator
Pharmacology & Drug Dosing Calculators
Digoxin Dosing Calculator
Pharmacology & Drug Dosing Calculators
Phenytoin Dosing Calculator
Pharmacology & Drug Dosing Calculators
